About
Reads cardiovascular risk (and now other systemic signals) off ordinary fundus photos. FDA Breakthrough Device designation for CLAiR (Nov 2023). Commercialising via eye-care channels and a 2025 consumer-longevity partnership with Lifeforce.
HQ: San Diego, USA (founded Auckland, NZ)
Funding
$8M Series A (Apr 2023, National Vision & Topcon Healthcare); ~$11M+ disclosed
Includes earlier NZ$3.35M seed.